The Science

Not a drug. Not a stem cell. A reset for the immune system.

In ALS, the immune system turns on the body it's meant to protect. SELtx™ uses your own blood to switch chronic inflammatory cells back into healers — in one 30-minute closed loop.

See the proof Talk to our team
The Root Issue

The same immune cells that protect you can turn against you.

Think of it as a switch with two settings. In healthy tissue it stays balanced. In ALS it gets stuck on "attack" — and the ratio between the two states tracks how fast the disease moves.

M1 · Mr. Hyde

The "killer" state

Chronically activated M1 macrophages drive inflammation and attack motor neurons. The longer they dominate, the faster ALS progresses.

M2 · Dr. Jekyll

The "healer" state

M2 macrophages calm inflammation and support repair. Shift the balance back toward M2 and you change the disease's trajectory.

How SELtx™ Treats ALS

One closed loop. Four steps. Thirty minutes.

SELtx™ is a cell-based platform — not a stem-cell therapy. Your blood never leaves a sterile, closed circuit.

~30 min sterile closed loop 01 Draw 02 Activate 03 Signal 04 Re-infuse
01

Draw

~300 mL of blood — less than a standard donation — in a routine clinical setting.

02

Activate

Controlled hyperoxia and mechanotransduction trigger apoptosis — creating signaling "apoptogenics."

03

Signal

Those signals drive efferocytosis — flipping M1 "killer" cells into M2 "healer" cells.

04

Re-infuse

The treated blood returns. The immune system stops attacking and starts repairing.

The Main Medical Breakthrough

We rebalance immunity instead of shutting it down.

No drugs

Nothing synthetic is introduced. The therapy works with your own cells and their natural signals.

No stem cells

A cell-based platform that needs no stem cells, donor material, or genetic modification.

No immunosuppression

It resets the balance rather than broadly suppressing it — avoiding the toxicity of shutting immunity off.

Precision apoptogenics Efferocytosis in action Closed-loop, point-of-care
How We Quantify This

We don't just claim the shift. We measure it.

In transgenic SOD1 ALS models, SELtx™ produced a validated M1-to-M2 shift — tracked with established immune biomarkers — alongside preserved motor function. The work was conducted with the Indiana University School of Medicine.

See the full study
TNF-α · inflammatory cytokine▼ reduced
NOS1 · M1 "killer" marker▼ reduced
CD206 · M2 "healer" marker▲ elevated
M1 → M2 phenotype shiftconfirmed
Motor-function significancep < 0.008
Validated with Indiana University School of Medicine
Protected Worldwide

A platform built on a growing global IP portfolio.

The reactor and method behind SELtx™ are protected by granted patents and active filings across major markets.

United States Canada Japan India China · pending Australia · pending
US · 2022

Gas Treatment Delivery Systems and Methods

U.S. Patent No. 1171579 — A controlled, precise gas–fluid contact reactor that reacts hyperoxia with whole blood, together with mechanotransduction, to induce apoptotic cells — "apoptogenics."

Japan · 2024

Gas Treatment Delivery Systems and Methods

Japan Patent No. 75297259 — The core SELtx™ method, protected in Japan — extending global coverage of the apoptogenic reactor and process.

US

Ozone Delivery System (Variable-Pitch Gas–Fluid Contact Device)

U.S. Patent No. 7,736,494 B2 — Precision control of oxidative stress for accurate dosing and regulation of cellular apoptogenesis.

Int’l PCT

Treatment of Inflammatory Disorders, Cardiovascular Disease & Stroke with Ozone

PCT/US2010/001785 — A hyperoxia delivery system for a measured reaction with a given biological fluid.

Int’l PCT

Gas Treatment Delivery System and Methods

PCT/US2017/047690 — Filed across China, India, Canada, and Australia — widening protection of the platform’s reactor and method.

See It Work

The mechanism is real. Here's the proof in living models.

View the preclinical study